What Happens After an Elevated PSA Test: The Experience of 13,591 Veterans
暂无分享,去创建一个
Steven B. Zeliadt | Ruth Etzioni | Daniel W. Lin | Ruth Etzioni | D. Lin | R. Hoffman | S. Zeliadt | Richard M. Hoffman | Van Anh T. Ginger | V. Ginger
[1] D. Bates,et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. , 2004, The American journal of medicine.
[2] Y. Taylor,et al. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006. , 2009, Journal of the National Medical Association.
[3] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[4] D. Federman,et al. Informed consent for PSA screening: does it happen? , 1999, Effective clinical practice : ECP.
[5] D. Merenstein. A piece of my mind. Winners and losers. , 2004, JAMA.
[6] Adam S. Kibel,et al. Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .
[7] F. Gilliland,et al. Prostate-specific antigen testing practices and outcomes , 1998, Journal of General Internal Medicine.
[8] J. Goodwin,et al. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer , 2008, BMC health services research.
[9] Barnett S Kramer,et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. , 2005, The Journal of urology.
[10] Brian J Zikmund-Fisher,et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). , 2009, Archives of internal medicine.
[11] M. Brundage,et al. Practical issues in assisting shared decision‐making , 2000, Health expectations : an international journal of public participation in health care and health policy.
[12] Steven H. Woolf,et al. Patient Education on Prostate Cancer Screening and Involvement in Decision Making , 2007, The Annals of Family Medicine.
[13] C. Maynard,et al. Data resources in the Department of Veterans Affairs. , 2004, Diabetes care.
[14] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[15] G. Annas,et al. Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer , 1997, Journal of Law, Medicine & Ethics.
[16] I. Thompson,et al. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. , 2009, The Journal of urology.
[17] G. Murphy,et al. American Cancer Society guideline for the early detection of prostate cancer: Update 1997 , 1997, CA: a cancer journal for clinicians.
[18] Harry J de Koning,et al. Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.
[19] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[20] A. Lu,et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.
[21] I. Nyirjesy. Enthusiasm for Cancer Screening in the United States , 2008 .
[22] Angela Fagerlin,et al. Evidence-based patient choice: a prostate cancer decision aid in plain language , 2005, BMC Medical Informatics Decis. Mak..
[23] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[24] Richard L. Morrill,et al. METROPOLITAN, URBAN, AND RURAL COMMUTING AREAS: TOWARD A BETTER DEPICTION OF THE UNITED STATES SETTLEMENT SYSTEM , 1999 .
[25] S. Goodrich,et al. A Piece of My Mind , 2014 .
[26] Robert J Volk,et al. Trials of decision aids for prostate cancer screening: a systematic review. , 2007, American journal of preventive medicine.
[27] M. Elhilali,et al. Benign prostatic hyperplasia: from A - Z. , 2003, The Canadian journal of urology.
[28] Stacey L Sheridan,et al. Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. , 2004, American journal of preventive medicine.
[29] J. Gohagan,et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial , 2008, BJU international.
[30] P. Loehrer. PSA Screening Among Elderly Men With Limited Life Expectancies , 2008 .
[31] E. Yano,et al. Urologic Diseases in America Project , 2005 .
[32] D. Lishner,et al. Rural definitions for health policy and research. , 2005, American journal of public health.
[33] J. S. Long,et al. Regression models for categorical dependent variables using Stata, 2nd Edition , 2005 .
[34] Purushottam W. Laud,et al. An Algorithm for the Use of Medicare Claims Data to Identify Women with Incident Breast Cancer , 2004 .
[35] Stephen L. Hillis,et al. Prevalence of delayed clinician response to elevated prostate-specific antigen values. , 2008, Mayo Clinic proceedings.
[36] Michael W Kattan,et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Reiber,et al. Veterans Using and Uninsured Veterans Not Using Veterans Affairs (VA) Health Care , 2007, Public health reports.
[38] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.